For instance, in oxaliplatin-resistant colorectal cancer cells, the expression of hexokinase 2 (HK2) and lactate dehydrogenase A (LDHA) is markedly upregulated, thereby enhancing glycolytic flux and reducing intracellular drug accumulation (95–97). Here, LDHA is linked to colorectal cancer.